Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
pTVG-AR and Checkpoint Blockade in High-Risk Prostate Cancer
NCT04989946Phase 2Active, not recruiting
- Sponsor
- University of Wisconsin–Madison
- Start
- Dec 2021
- Primary completion
- Dec 2026
- Modality
- Prophylactic Vaccines, DNA Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of pTVG-AR in prostate cancer (PCa), sponsored by University of Wisconsin–Madison. Started Dec 2021; status: active, not recruiting.
02
Drugs
pTVG-AR
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT04989946.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04989946.